References
- World Health OrganizationWorld Cancer Report 2014 Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?codlan=1&codcol=76&codcch=31Accessed June 17, 2017
- YangPEpidemiology of lung cancer prognosis: quantity and quality of lifeMethods Mol Biol200947146948619109795
- Institut National du CancerLe cancer du poumon: points clés [Lung cancer: key points] Available from: http://www.e-cancer.fr/Patients-et-proches/Les-cancers/Cancer-du-poumon/Quelques-chiffresAccessed June 17, 2017 French
- SherTDyGKAdjeiAASmall cell lung cancerMayo Clin Proc200883335536718316005
- ReckMPopatSReinmuthNMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii27iii3925115305
- LosannoTGridelliCSafety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancerExpert Opin Drug Saf201615683785127007279
- SantabarbaraGMaionePRossiAGridelliCPharmacotherapeutic options for treating adverse effects of Cisplatin chemotherapyExpert Opin Pharmacother201617456157026581586
- DiBSWeiKPTianJHEffectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysisAsian Pac J Cancer Prev20141583419342424870732
- BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
- BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med2015373212313526028407
- HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet2016387100271540155026712084
- ReckMRodriguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
- PatelJDSocinskiMAGaronEBPointBreak: a randomized Phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancerJ Clin Oncol201331344349435724145346
- ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med2005353212313216014882
- GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomized phase 3 trialLancet2014384994466567324933332
- US Department of Health and Human ServicesNational Institutes of HealthNational Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE); Version 4.02009 Available from: https://www.eortc.be/services/doc/ctc/Accessed June 17, 2017
- BanzKBischoffHBrunnerMComparison of treatment costs of Grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainLung Cancer201174352953421592611
- NuijtenMJde Castro CarpenoJChouaidCA cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerLung Cancer201276346547122153602
- WehlerEZhaoZPinar BilirSMunakataJBarberBEconomic burden of toxicities associated with treating metastatic melanoma in eight countriesEur J Health Econ2017181495826721505
- VoukKBenterUAmonkarMMCost and economic burden of adverse events associated with metastatic melanoma treatments in five countriesJ Med Econ201619990091227123564
- RicciPChantryMDetournayBPoutignatNKusnik-JoinvilleORaimondVReimbursed health expenditures of people treated for diabetes by the French National Health Insurance Fund: 2001 and 2007 ENTRED SurveysBulletin Epidémiologique Hebdomadaire20094243464469
- ChouaidCAngevinEGodardCCosts of adverse events associated with cancer therapies in non-small cell lung cancer in FrancePoster presented at: ISPOR 19th Annual European CongressOctober 29 to November 2, 2016Vienna, Austria
- ChouaidCAngevinEGodardCCosts of adverse events associated with cancer therapies in non-small cell lung cancer in France. In: Poster abstractsValue Health201619A743